Vertex Pharmaceuticals Inc has priced its three-drug combination for cystic fibr...
- Vertex Pharmaceuticals Inc has priced its three-drug combination for cystic fibrosis at $311,503 per year, after winning early U.S. approval on Monday.
The U.S. Food and Drug Administration approval, which comes five months ahead of the agency’s previously announced action date, greatly expands the percentage of cystic fibrosis patients that Vertex can treat. Trikafta is the first approved treatment that is effective for patients 12 years and older, who have a genetic mutation which affects 90% of CF patients or roughly 27,000 people in the United States, the agency said.
However, the approval comes at a time when the drugmaker has been receiving push back from healthcare payers for the price of its existing CF therapies.
Brasil Últimas Notícias, Brasil Manchetes
Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.
FDA approves new breakthrough therapy for cystic fibrosisToday's US_FDA approval, makes treatment available to 90% of cystic fibrosis patients 12 & older – some who previously had no options – and giving others in the community access to an additional effective therapy.
Consulte Mais informação »
11 Surprising Facts About Botox You Probably Didn't KnowIncluding the ideal age to start treatment.
Consulte Mais informação »
China Sept home price growth flatlines, fewer cities see price gainsNew home prices in China grew at a steady pace in September, with fewer cities r...
Consulte Mais informação »
China September home price growth flatlines, fewer cities see price gainsNew home prices in China grew at a steady pace in September, with fewer cities r...
Consulte Mais informação »
I'm 26, I Make $77,000 & I Don't Pay Income Tax'I've been looking for a new job for the last few months and have made it to the final round of interviews several times only to not get the job in the end. It is super frustrating and I celebrate everyone who has done this without going slightly crazy.'
Consulte Mais informação »